Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 3
2007 2
2008 1
2009 4
2010 7
2011 10
2012 12
2013 10
2014 12
2015 10
2016 13
2017 7
2018 7
2019 4
2020 8
2021 6
2022 9
2023 9
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

113 results

Results by year

Filters applied: . Clear all
Page 1
Third-line treatment patterns in HER2-positive metastatic breast cancer: a retrospective analysis of real-world data in Canada.
Gambaro K, Groleau M, McNamara S, Awan A, Salem M, Abdelsalam M, St-Hilaire E, Vincent F, Carrier J, MacKay H, Provencher L, Boudreau D, Hamilou Z, Saad F, Ferrario C, Batist G, Marques M. Gambaro K, et al. Among authors: mackay h. J Pharm Pharm Sci. 2023 Dec 13;26:12078. doi: 10.3389/jpps.2023.12078. eCollection 2023. J Pharm Pharm Sci. 2023. PMID: 38152647 Free PMC article.
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer.
Rimel BJ, Enserro D, Bender DP, Jackson CG, Tan A, Alluri N, Borowsky M, Moroney J, Hendrickson AW, Backes F, Swisher E, Powell M, MacKay H. Rimel BJ, et al. Among authors: mackay h. Cancer. 2024 Apr 15;130(8):1234-1245. doi: 10.1002/cncr.35151. Epub 2023 Dec 21. Cancer. 2024. PMID: 38127487 Clinical Trial.
Clinical Validation of Human Papilloma Virus Circulating Tumor DNA for Early Detection of Residual Disease After Chemoradiation in Cervical Cancer.
Han K, Zou J, Zhao Z, Baskurt Z, Zheng Y, Barnes E, Croke J, Ferguson SE, Fyles A, Gien L, Gladwish A, Lecavalier-Barsoum M, Lheureux S, Lukovic J, Mackay H, Marchand EL, Metser U, Milosevic M, Taggar AS, Bratman SV, Leung E. Han K, et al. Among authors: mackay h. J Clin Oncol. 2024 Feb 1;42(4):431-440. doi: 10.1200/JCO.23.00954. Epub 2023 Nov 16. J Clin Oncol. 2024. PMID: 37972346 Free PMC article.
A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers.
Gonzalez-Ochoa E, Milosevic M, Corr B, Abbruzzese JL, Girda E, Miller RW, Croke J, Mackay H, Lee YC, Bowering V, Ramsahai J, Wang L, D'Souza A, Kunos CA, Oza AM, Lheureux S. Gonzalez-Ochoa E, et al. Among authors: mackay h. Int J Gynecol Cancer. 2023 Aug 7;33(8):1208-1214. doi: 10.1136/ijgc-2023-004491. Int J Gynecol Cancer. 2023. PMID: 37380217 Free PMC article. Clinical Trial.
Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775.
Makker V, Colombo N, Casado Herráez A, Monk BJ, Mackay H, Santin AD, Miller DS, Moore RG, Baron-Hay S, Ray-Coquard I, Ushijima K, Yonemori K, Kim YM, Guerra Alia EM, Sanli UA, Bird S, Orlowski R, McKenzie J, Okpara C, Barresi G, Lorusso D. Makker V, et al. Among authors: mackay h. J Clin Oncol. 2023 Jun 1;41(16):2904-2910. doi: 10.1200/JCO.22.02152. Epub 2023 Apr 14. J Clin Oncol. 2023. PMID: 37058687 Free PMC article. Clinical Trial.
Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma.
Madariaga A, Garg S, Tchrakian N, Dhani NC, Jimenez W, Welch S, MacKay H, Ethier JL, Gilbert L, Li X, Rodriguez A, Chan L, Bowering V, Clarke B, Zhang T, King I, Downs G, Stockley T, Wang L, Udagani S, Oza AM, Lheureux S. Madariaga A, et al. Among authors: mackay h. Nat Commun. 2023 Mar 15;14(1):1452. doi: 10.1038/s41467-023-37084-w. Nat Commun. 2023. PMID: 36922497 Free PMC article. Clinical Trial.
Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry.
Vermij L, Jobsen JJ, León-Castillo A, Brinkhuis M, Roothaan S, Powell ME, de Boer SM, Khaw P, Mileshkin LR, Fyles A, Leary A, Genestie C, Jürgenliemk-Schulz IM, Crosbie EJ, Mackay HJ, Nijman HW, Nout RA, Smit VTHBM, Creutzberg CL, Horeweg N, Bosse T; TransPORTEC Consortium. Vermij L, et al. Among authors: mackay hj. Br J Cancer. 2023 Mar;128(7):1360-1368. doi: 10.1038/s41416-023-02141-0. Epub 2023 Jan 23. Br J Cancer. 2023. PMID: 36690721 Free PMC article.
Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts.
Fremond S, Andani S, Barkey Wolf J, Dijkstra J, Melsbach S, Jobsen JJ, Brinkhuis M, Roothaan S, Jurgenliemk-Schulz I, Lutgens LCHW, Nout RA, van der Steen-Banasik EM, de Boer SM, Powell ME, Singh N, Mileshkin LR, Mackay HJ, Leary A, Nijman HW, Smit VTHBM, Creutzberg CL, Horeweg N, Koelzer VH, Bosse T. Fremond S, et al. Among authors: mackay hj. Lancet Digit Health. 2023 Feb;5(2):e71-e82. doi: 10.1016/S2589-7500(22)00210-2. Epub 2022 Dec 7. Lancet Digit Health. 2023. PMID: 36496303 Free article. Clinical Trial.
113 results